[go: up one dir, main page]

HUE067367T2 - ANTI-FOLR1 immunkonjugátum adagolási rendszer - Google Patents

ANTI-FOLR1 immunkonjugátum adagolási rendszer

Info

Publication number
HUE067367T2
HUE067367T2 HUE19199163A HUE19199163A HUE067367T2 HU E067367 T2 HUE067367 T2 HU E067367T2 HU E19199163 A HUE19199163 A HU E19199163A HU E19199163 A HUE19199163 A HU E19199163A HU E067367 T2 HUE067367 T2 HU E067367T2
Authority
HU
Hungary
Prior art keywords
dosing regimens
folr1 immunoconjugate
immunoconjugate dosing
folr1
regimens
Prior art date
Application number
HUE19199163A
Other languages
English (en)
Inventor
Robert J Lutz
Jose Ponte
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE067367(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of HUE067367T2 publication Critical patent/HUE067367T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Botany (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE19199163A 2013-10-08 2014-10-08 ANTI-FOLR1 immunkonjugátum adagolási rendszer HUE067367T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361888337P 2013-10-08 2013-10-08
US201361888365P 2013-10-08 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US201462004815P 2014-05-29 2014-05-29

Publications (1)

Publication Number Publication Date
HUE067367T2 true HUE067367T2 (hu) 2024-10-28

Family

ID=52813740

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE14852834A HUE046696T2 (hu) 2013-10-08 2014-10-08 Anti-FOLR1 immunkonjugátum adagolási sémái
HUE19199163A HUE067367T2 (hu) 2013-10-08 2014-10-08 ANTI-FOLR1 immunkonjugátum adagolási rendszer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE14852834A HUE046696T2 (hu) 2013-10-08 2014-10-08 Anti-FOLR1 immunkonjugátum adagolási sémái

Country Status (29)

Country Link
US (3) US20150132323A1 (hu)
EP (3) EP4424323A3 (hu)
JP (5) JP6463744B2 (hu)
KR (7) KR102303874B1 (hu)
CN (1) CN106164093A (hu)
AU (4) AU2014331964C1 (hu)
BR (1) BR112016007479A2 (hu)
CA (1) CA2926325C (hu)
CY (1) CY1122449T1 (hu)
DK (2) DK3653228T3 (hu)
ES (2) ES2983055T3 (hu)
FI (1) FI3653228T3 (hu)
HR (2) HRP20192140T1 (hu)
HU (2) HUE046696T2 (hu)
IL (4) IL298044B2 (hu)
LT (2) LT3055332T (hu)
MX (2) MX384973B (hu)
MY (1) MY174670A (hu)
NZ (2) NZ718766A (hu)
PL (2) PL3653228T3 (hu)
PT (2) PT3653228T (hu)
RS (2) RS59644B1 (hu)
RU (1) RU2696579C2 (hu)
SG (3) SG11201602361UA (hu)
SI (2) SI3055332T1 (hu)
SM (1) SMT201900694T1 (hu)
UA (1) UA119541C2 (hu)
WO (1) WO2015054400A2 (hu)
ZA (1) ZA201902009B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2538976B8 (en) 2010-02-24 2017-05-24 ImmunoGen, Inc. Immunoconjugates against folate receptor 1 and uses thereof
MX346555B (es) 2011-04-01 2017-03-24 Immunogen Inc Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
LT2890717T (lt) 2012-08-31 2020-06-10 Immunogen, Inc. Diagnostiniai tyrimai ir rinkiniai, skirti foliato receptoriaus 1 nustatymui
US20140363451A1 (en) * 2013-05-14 2014-12-11 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
CA3222465A1 (en) 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
CN108601828B (zh) * 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
MX2019013753A (es) * 2017-05-16 2020-07-20 Immunogen Inc Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1.
US12071477B2 (en) * 2017-09-18 2024-08-27 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugated with hemiasterlins
CA3091683A1 (en) 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
EP3821006A4 (en) * 2018-07-09 2022-12-07 Multitude Inc. FOLATE RECEPTOR ALPHA SPECIFIC ANTIBODIES
JP7585230B2 (ja) 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド バイパラトピックＦＲ－α抗体及びイムノコンジュゲート
IL308992A (en) * 2021-06-04 2024-01-01 Immunogen Inc Cancer treatment in patients with soluble FR-alpha
KR20240108799A (ko) * 2021-12-01 2024-07-09 서트로 바이오파마, 인크. 항 엽산 수용체 접합체 암 요법
CN116333135A (zh) * 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
WO1998020932A2 (en) * 1996-11-15 1998-05-22 Baxter International Inc. Conditioning for allogeneic stem cell transplantation
EP1133565B1 (en) 1999-07-02 2010-09-22 MorphoSys AG Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
US20080131366A1 (en) * 2003-03-17 2008-06-05 Manohar Ratnam Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
CA2602585A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
WO2007037910A2 (en) * 2005-09-14 2007-04-05 Fred Hutchinson Cancer Research Center Specific removal of activated immune cells
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
WO2009134977A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Cross-linkers and their uses
AU2009243009B2 (en) 2008-04-30 2014-09-11 Immunogen, Inc Potent conjugates and hydrophilic linkers
LT2378876T (lt) * 2008-12-19 2019-04-25 Medicis Pharmaceutical Corporation Mažesnio stiprumo dozės imikvimodo kompozicijos ir trumpi dozavimo režimai, skirti aktininės keratozės gydymui
RU2012120691A (ru) * 2009-10-21 2013-11-27 Иммьюноджен, Инк. Новый режим дозирования и способ лечения
EP2538976B8 (en) 2010-02-24 2017-05-24 ImmunoGen, Inc. Immunoconjugates against folate receptor 1 and uses thereof
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
WO2012061759A2 (en) * 2010-11-05 2012-05-10 Morphotek Inc. Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
MX346555B (es) * 2011-04-01 2017-03-24 Immunogen Inc Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
WO2012138749A1 (en) * 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
LT2890717T (lt) * 2012-08-31 2020-06-10 Immunogen, Inc. Diagnostiniai tyrimai ir rinkiniai, skirti foliato receptoriaus 1 nustatymui
CN105338973A (zh) * 2013-04-08 2016-02-17 博格有限责任公司 使用辅酶q10联合疗法治疗癌症
US20140363451A1 (en) * 2013-05-14 2014-12-11 Immunogen, Inc. Anti-FOLR1 Immunoconjugate Dosing Regimens
CA3222465A1 (en) * 2013-08-30 2015-03-05 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
CN108601828B (zh) * 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合

Also Published As

Publication number Publication date
KR102639861B1 (ko) 2024-02-22
AU2014331964A1 (en) 2016-04-28
EP4424323A3 (en) 2024-11-13
JP6581279B2 (ja) 2019-09-25
KR20240027861A (ko) 2024-03-04
RU2016114708A3 (hu) 2018-07-31
JP2024016239A (ja) 2024-02-06
IL298044B1 (en) 2024-07-01
RS65798B1 (sr) 2024-08-30
JP6463744B2 (ja) 2019-02-06
SG10202102555TA (en) 2021-04-29
DK3055332T3 (da) 2019-12-09
SG10201907042PA (en) 2019-09-27
WO2015054400A2 (en) 2015-04-16
EP3055332A2 (en) 2016-08-17
AU2014331964B2 (en) 2018-09-13
KR102303874B1 (ko) 2021-09-17
MX384973B (es) 2025-03-14
EP4424323A2 (en) 2024-09-04
IL298044B2 (en) 2024-11-01
EP3653228A1 (en) 2020-05-20
IL244772B (en) 2019-05-30
CA2926325A1 (en) 2015-04-16
CY1122449T1 (el) 2021-01-27
EP3055332B1 (en) 2019-09-25
ZA201902009B (en) 2020-10-28
UA119541C2 (uk) 2019-07-10
KR20230145544A (ko) 2023-10-17
KR20210041124A (ko) 2021-04-14
AU2020264270A1 (en) 2020-11-26
AU2024201615A1 (en) 2024-04-04
LT3653228T (lt) 2024-07-25
KR102115217B1 (ko) 2020-05-26
PT3653228T (pt) 2024-07-17
IL313730A (en) 2024-08-01
RU2696579C2 (ru) 2019-08-05
JP2016534039A (ja) 2016-11-04
US20150132323A1 (en) 2015-05-14
SG11201602361UA (en) 2016-04-28
JP2021178847A (ja) 2021-11-18
HRP20240917T1 (hr) 2024-10-11
NZ757964A (en) 2022-07-01
US20240368270A1 (en) 2024-11-07
FI3653228T3 (fi) 2024-07-04
PL3055332T3 (pl) 2020-02-28
PL3653228T3 (pl) 2024-11-12
US20210155688A1 (en) 2021-05-27
MY174670A (en) 2020-05-06
KR20160079797A (ko) 2016-07-06
WO2015054400A3 (en) 2015-06-25
AU2018278880A1 (en) 2019-01-03
KR20220136468A (ko) 2022-10-07
NZ718766A (en) 2020-02-28
EP3653228B1 (en) 2024-05-15
DK3653228T3 (da) 2024-07-15
HUE046696T2 (hu) 2020-03-30
JP2019031568A (ja) 2019-02-28
JP7386208B2 (ja) 2023-11-24
AU2020264270B2 (en) 2024-01-18
KR20200058592A (ko) 2020-05-27
HK1226671A1 (en) 2017-10-06
AU2014331964C1 (en) 2019-10-31
ES2983055T3 (es) 2024-10-21
BR112016007479A2 (pt) 2017-09-12
RU2016114708A (ru) 2017-11-15
SI3653228T1 (sl) 2024-09-30
MX2016004411A (es) 2016-07-05
SMT201900694T1 (it) 2020-01-14
SI3055332T1 (sl) 2020-02-28
KR102115217B9 (ko) 2021-12-24
IL298044A (en) 2023-01-01
PT3055332T (pt) 2019-12-09
LT3055332T (lt) 2020-04-10
IL265586A (en) 2019-05-30
JP2019218386A (ja) 2019-12-26
KR20210118220A (ko) 2021-09-29
CA2926325C (en) 2023-08-01
RS59644B1 (sr) 2020-01-31
ES2759426T3 (es) 2020-05-11
CN106164093A (zh) 2016-11-23
EP3055332A4 (en) 2017-05-31
IL244772A0 (en) 2016-04-21
HRP20192140T1 (hr) 2020-03-06
MX2021009222A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
IL268180A (en) Dosing regimens of anti-FOLR1 immunoconjugate
IL265586A (en) Dosing regimens of anti–folr1 immunoconjugate
PL2798995T3 (pl) Urządzenie dozujące
SG11201508538SA (en) Complex
EP2960834A4 (en) CONTAINER
BR112016012642A2 (pt) recipiente de distribuição
ES1135414Y (es) Envase
CL2014000083S1 (es) Envase
PL3030193T3 (pl) Urządzenie dozujące
CL2014001698S1 (es) Contenedor
HUE058938T2 (hu) Tartály
HUE041387T2 (hu) Átfolyásmérõ
FI20135154L (fi) Kontti
EP2969903A4 (en) INTERMITTENT DOSING
GB201301046D0 (en) Dosing mechanism
CL2014001028S1 (es) Envase
CL2014001696S1 (es) Contenedor
CL2014001697S1 (es) Contenedor
DOS2013000271S (es) Contenedor
GB201304599D0 (en) Dosing regimen
GB201320647D0 (en) Immunoconjugates
GB201318043D0 (en) Immunoconjugates
GB201307599D0 (en) Immunoconjugates
HUE063928T2 (hu) Tartály
CL2014001699S1 (es) Contenedor